Meanwhile, immunohistochemical evaluation of PD-L2 expression in NSCLC specimens showed that PD-L2 expression may be a potential biomarker for response to PD-1/PD-L1-targeted immunotherapy (Matsubara et al. 2019). Here, PDCD1 is linked to non-small cell lung carcinoma.